CONFERENCE UPDATE : EULAR 2020

Phase 3 study of avacopan revealed higher remission rates for anti-neutrophil cytoplasmic antibody-associated vasculitis

31 Aug 2020

FINDINGS

Primary Endpoints:

  •  

At week 26, 72.3% of patients in the avacopan group achieved remission compared to 70.1% of patients in the prednisone group (p<0.0001 for non-inferiority)

  •  

At week 52, 65.7% of the avacopan arm's cohort group achieved sustained remission compared to 54.9% in the prednisone arm group (p=0.0066 for the superiority of avacopan)

Secondary Endpoints:

  •  

There was a significant decrease in glucocorticoid-related toxicity for patients treated with avacopan in contrast to the control group, as indicated by the Glucocorticoid Toxicity Index of Cumulative Worsening Score (p=0.0002) and Aggregate Improvement Score (p=0.0082) results

  •  

At week 26, the average glucocorticoid toxicity index worsening score was 39.7% in the avacopan arm versus 56.6% in the control group

  •  

Patients treated with avacopan experienced a steroid-sparing effect

  •  

At 52 weeks, for the subgroup of patients with renal disease at baseline treated with avacopan, there was a mean increase in estimated glomerular filtration rate (eGFR) of 7.3mL/min/1.73m2 as compared to 4.0mL/min/1.73m2 increase in the prednisone group (p=0.0259)

  •  

Patients in both the avacopan and prednisone group experienced severe adverse events, 42.2% and 45.1% respectively, that were consistent with previous AAV trials

 

" Avacopan provides not only another option for patients and providers to use and treat, but we think it will be a terrific option for both new and relapsing disease”

Get access to our exclusive articles.